Details of Disease

General Information of Disease (ID: DIS3MMH9)

Disease Name	Cutaneous melanoma
Synonyms	malignant melanoma of skin of upper limb; zone of skin melanoma; malignant cutaneous melanoma; malignant melanoma (of skin), stage unspecified; zone of skin melanoma (disease); malignant neck melanoma; malignant lower limb melanoma; cutaneous melanoma; melanoma of the skin; cutaneous (skin) melanoma; malignant lip melanoma; cutaneous melanoma (disease); malignant trunk melanoma; malignant ear melanoma; malignant melanoma of skin stage unspecified; malignant melanoma of skin of lower limb; malignant scalp melanoma; malignant melanoma of skin of trunk except scrotum; skin, melanoma; malignant melanoma of ear and/or external auricular canal; malignant upper limb melanoma; malignant melanoma of skin; skin melanoma; melanoma of skin; melanoma (disease) of zone of skin
Disease Class	2C30: Melanoma
Definition	A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.
Disease Hierarchy	DIS1RRCY: Melanoma DISO91PH: Melanocytic skin neoplasm DISTM18U: Skin cancer DIS3MMH9: Cutaneous melanoma
ICD Code	ICD-11 ICD-11: 2C30 ICD-9 ICD-9: 172 Expand ICD-11 '2C30.Z Expand ICD-9 172
Disease Identifiers	MONDO ID MONDO_0005012 MESH ID D000096142 UMLS CUI C0151779 MedGen ID 57486 HPO ID HP:0012056 SNOMED CT ID 93655004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldesleukin	DM4YMIS	Approved	NA	[1]
Carboplatin	DMG281S	Approved	Small molecular drug	[2]
Fludarabine	DMVRLT7	Approved	Small molecular drug	[3]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[4]
Tebentafusp	DMUJ1WV	Approved	Monoclonal antibody	[5]
Temozolomide	DMKECZD	Approved	Small molecular drug	[6]
Tremetinib	DMMAO6M	Approved	NA	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nemvaleukin alfa	DMOAZHY	Phase 3	Fusion protein	[8]
PV-10	DM95UYC	Phase 3	Small molecular drug	[9]
PLX-4720	DMBK9AM	Phase 1	Small molecular drug	[10]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 77 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD163	TTTZ9DE	Limited	Biomarker	[11]
CTNNB1	TTRPKQG	Limited	Biomarker	[12]
DTL	TT8396I	Limited	Altered Expression	[13]
GNA11	TTSRXJW	Limited	Genetic Variation	[14]
IFNW1	TTS2TGF	Limited	Genetic Variation	[15]
KDM5A	TTIG67W	Limited	Biomarker	[16]
KMO	TTIY56R	Limited	Genetic Variation	[17]
KYNU	TTWQM3J	Limited	Genetic Variation	[17]
MCM6	TTQGKSD	Limited	Biomarker	[18]
MCM7	TT1RM3F	Limited	Altered Expression	[19]
NEK2	TT3VZ24	Limited	Altered Expression	[20]
PDPK1	TTYMGWX	Limited	Altered Expression	[21]
PRKCE	TT57MT2	Limited	Biomarker	[22]
PRTN3	TT5MLC4	Limited	Genetic Variation	[23]
PTEN	TTXJ3W7	Limited	Genetic Variation	[24]
RAC1	TT2M9CG	Limited	Genetic Variation	[23]
RAF1	TTAN5W2	Limited	Genetic Variation	[14]
RNASEL	TT7V0K4	Limited	Biomarker	[25]
SDHD	TTVH9W8	Limited	Genetic Variation	[26]
VSIR	TT51SK8	Limited	Altered Expression	[27]
MAP3K14	TT4LIAC	Disputed	Biomarker	[28]
NACC1	TT4AQ5F	Disputed	Altered Expression	[29]
CDH1	TTLAWO6	moderate	Genetic Variation	[30]
GNAO1	TTAXD8Z	moderate	Genetic Variation	[31]
HLA-DQB2	TTL7VOU	moderate	Genetic Variation	[31]
HRAS	TT28ZON	moderate	Biomarker	[32]
KDM5B	TTCLI75	moderate	Altered Expression	[33]
MAGEA1	TT63M7Q	moderate	Altered Expression	[34]
MAP2K2	TT8H9GB	moderate	Genetic Variation	[14]
MELTF	TT8OBT3	moderate	Altered Expression	[35]
PIK3CA	TTEUNMR	moderate	Genetic Variation	[14]
PLP2	TTK5OG6	moderate	Altered Expression	[36]
TFAP2A	TTDY4BS	moderate	Altered Expression	[37]
AKT1	TTWTSCV	Strong	Biomarker	[19]
ARAF	TT5TURO	Strong	Genetic Variation	[14]
B2M	TTY7FKA	Strong	Genetic Variation	[14]
CASP10	TTX5HEK	Strong	Biomarker	[38]
CCND1	TTFCJ7S	Strong	Biomarker	[39]
CDCA8	TT04YCM	Strong	Altered Expression	[40]
CDK4	TT0PG8F	Strong	Genetic Variation	[14]
CNR1	TT6OEDT	Strong	Biomarker	[41]
CREB1	TTH4AN3	Strong	Biomarker	[42]
CREBBP	TTFRCTK	Strong	Genetic Variation	[14]
CSPG4	TT7MYXI	Strong	Biomarker	[43]
CXCR4	TTBID49	Strong	Biomarker	[44]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[14]
EGFL7	TT7WD0H	Strong	Altered Expression	[45]
EIF2AK4	TT9U4EP	Strong	Biomarker	[46]
EZH2	TT9MZCQ	Strong	Altered Expression	[47]
FANCA	TTV5HJS	Strong	Genetic Variation	[48]
FBXW7	TT29KY7	Strong	Genetic Variation	[14]
FTO	TTFW3BT	Strong	Genetic Variation	[48]
IDH1	TTV2A1R	Strong	Genetic Variation	[14]
IRF3	TTYR7OH	Strong	Genetic Variation	[14]
KIT	TTX41N9	Strong	Genetic Variation	[49]
MAGEA2	TTOZT28	Strong	Biomarker	[50]
MAP2K1	TTIDAPM	Strong	Genetic Variation	[14]
MAP2K7	TT6QY3J	Strong	Genetic Variation	[51]
MDM2	TT9TE0O	Strong	Altered Expression	[52]
MTAP	TTDBX7N	Strong	Genetic Variation	[53]
PDGFRA	TT8FYO9	Strong	Genetic Variation	[54]
PIGU	TT2LHI6	Strong	Genetic Variation	[48]
RET	TT4DXQT	Strong	Genetic Variation	[55]
SF3B1	TTL2WUI	Strong	Altered Expression	[49]
SLC7A11	TTBZMIO	Strong	Altered Expression	[56]
TDGF1	TTN7HMG	Strong	Biomarker	[57]
TRPM1	TTTDAI9	Strong	Biomarker	[58]
TYRP1	TTFRV98	Strong	Biomarker	[59]
VEGFC	TT0QUFV	Strong	Biomarker	[60]
CYP1B1	TTI84H7	Definitive	Genetic Variation	[48]
GRM1	TTVBPDM	Definitive	Biomarker	[61]
HDAC4	TTTQGH8	Definitive	Genetic Variation	[48]
MC1R	TT0MV2T	Definitive	Genetic Variation	[62]
MCAM	TTHRE05	Definitive	Biomarker	[63]
NES	TTHZ752	Definitive	Biomarker	[64]
PPARGC1B	TTKSQ3W	Definitive	Genetic Variation	[48]
TYR	TTULVH8	Definitive	Altered Expression	[65]
------------------------------------------------------------------------------------


⏷ Show the Full List of 77 DTT(s)

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCB5	DTKVEXO	Limited	Biomarker	[66]
ABCC11	DTWN7FC	Limited	Genetic Variation	[67]
SLC45A2	DTNCJAT	Limited	Genetic Variation	[68]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NNMT	DECVGJ3	Limited	Altered Expression	[69]
GSTM1	DEYZEJA	Definitive	Genetic Variation	[70]
------------------------------------------------------------------------------------

This Disease Is Related to 129 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACO1	OT2VUR7L	Limited	Genetic Variation	[15]
AGR3	OTONJPDP	Limited	Genetic Variation	[71]
AKT1S1	OT4JHN4Y	Limited	Altered Expression	[72]
ATF1	OT251CI0	Limited	Genetic Variation	[73]
ATP2B4	OTMWFDAC	Limited	Altered Expression	[74]
BRMS1	OTV5A6LL	Limited	Biomarker	[75]
BTRC	OT2EZDGR	Limited	Genetic Variation	[76]
CCNF	OTJFVU43	Limited	Biomarker	[77]
CD207	OTI9RUDN	Limited	Biomarker	[78]
CHAF1A	OTXSSY4H	Limited	Biomarker	[79]
CHAF1B	OTOMK4KH	Limited	Biomarker	[79]
CNOT7	OTJBKCPI	Limited	Biomarker	[79]
CNOT8	OT6CMCS0	Limited	Biomarker	[79]
DCTN2	OTMB4IXD	Limited	Biomarker	[80]
DCTN5	OTESGJ1N	Limited	Biomarker	[80]
EIF1AX	OTWG2LAB	Limited	Genetic Variation	[81]
FABP7	OTRE2H4G	Limited	Altered Expression	[82]
FERMT2	OTZNPWWX	Limited	Biomarker	[83]
GBP1	OTUM7RPJ	Limited	Biomarker	[84]
GOLM1	OTOZSV6O	Limited	Genetic Variation	[85]
GRWD1	OT6M13ZV	Limited	Altered Expression	[86]
HYAL2	OTTVINXW	Limited	Altered Expression	[87]
ING3	OTDIJXFP	Limited	Altered Expression	[88]
MAGI1	OTMV4ASV	Limited	Genetic Variation	[89]
MCM3	OTOOHQPM	Limited	Biomarker	[90]
MCM4	OT19PNNG	Limited	Altered Expression	[18]
MUC13	OTWKS9MF	Limited	Biomarker	[91]
MYH7B	OTCB2IJB	Limited	Genetic Variation	[92]
NAV2	OTGAOL01	Limited	Altered Expression	[93]
NFKBIZ	OTU728KS	Limited	Biomarker	[90]
PAX7	OTDMQRPO	Limited	Altered Expression	[94]
PLIN2	OTRXJ9UN	Limited	Altered Expression	[95]
PRDX6	OTS8KC8A	Limited	Genetic Variation	[23]
PREX1	OTUTPVA9	Limited	Biomarker	[96]
PREX2	OTYT1J6J	Limited	Genetic Variation	[24]
PSMD6	OTX59EGK	Limited	Genetic Variation	[97]
RAB8A	OTPB54Y3	Limited	Genetic Variation	[98]
RASSF10	OTGB7EBG	Limited	Posttranslational Modification	[99]
RBX1	OTYA1UIO	Limited	Altered Expression	[100]
RIT1	OTVNOGOH	Limited	Altered Expression	[100]
RNF2	OTFPLOIN	Limited	Altered Expression	[101]
SEC23A	OTBRNIJ3	Limited	Biomarker	[102]
SLN	OTERIU75	Limited	Biomarker	[103]
SPAAR	OTWXG2R8	Limited	Altered Expression	[104]
SYF2	OTY2ZW1H	Limited	Genetic Variation	[23]
TEAD4	OTJS0T2B	Limited	Genetic Variation	[105]
TTC4	OTAPMYXU	Limited	Genetic Variation	[106]
CCDC88C	OTIU02BS	Disputed	Biomarker	[107]
CDK15	OT8S67QS	Disputed	Biomarker	[28]
CDK16	OTUBXIIT	Disputed	Biomarker	[28]
CILK1	OTWOYEYP	Disputed	Biomarker	[28]
GC	OTWS63BY	Disputed	Genetic Variation	[108]
PRKACG	OTKOQYF8	Disputed	Biomarker	[28]
TLK1	OTICTXI8	Disputed	Biomarker	[28]
APAF1	OTJWIVY0	moderate	Genetic Variation	[109]
CADM1	OTRWG9QS	moderate	Posttranslational Modification	[110]
CCDC6	OTXRQDYG	moderate	Genetic Variation	[55]
CDKAL1	OTA0SGNE	moderate	Genetic Variation	[30]
CDKN3	OTBE3H07	moderate	Genetic Variation	[111]
DBF4	OTBL7JHQ	moderate	Altered Expression	[112]
FBLN1	OT5MHHOP	moderate	Posttranslational Modification	[113]
GPR37	OTIMDDI3	moderate	Genetic Variation	[30]
INPP5K	OTQFLQKA	moderate	Biomarker	[114]
JMJD6	OTILR7E4	moderate	Biomarker	[115]
MAGED4B	OTO37U7W	moderate	Altered Expression	[34]
MAML2	OT1TSVAR	moderate	Biomarker	[116]
MAP2	OT6UYT3X	moderate	Altered Expression	[117]
MIB2	OTJCC3HS	moderate	Biomarker	[118]
MINDY4	OTBZ2SZB	moderate	Altered Expression	[119]
NLRP2	OTJA81JU	moderate	Biomarker	[120]
PAX3	OTN5PJZV	moderate	Altered Expression	[121]
PITX1	OTA0UN4C	moderate	Altered Expression	[122]
PLAA	OTZ7NJGA	moderate	Biomarker	[123]
PLEKHM2	OT4ZYV73	moderate	Biomarker	[114]
PRDM16	OT0BGA27	moderate	Biomarker	[124]
RASSF8	OTXKGIB3	moderate	Biomarker	[125]
RMDN2	OTK5WSFI	moderate	Genetic Variation	[30]
S100A13	OT582SUS	moderate	Biomarker	[126]
SNW1	OTKWG3PS	moderate	Biomarker	[114]
SOX10	OTF25ULQ	moderate	Biomarker	[127]
SPHKAP	OT5RHUYJ	moderate	Biomarker	[114]
STN1	OT8UWRA3	moderate	Genetic Variation	[30]
TAS2R38	OTX5MM36	moderate	Genetic Variation	[55]
ARNT	OTMSIEZY	Strong	Altered Expression	[128]
BCL2L12	OTS6IFZY	Strong	Genetic Variation	[14]
CCL25	OTLWJ8CJ	Strong	Biomarker	[129]
CHD5	OTS5EVHH	Strong	Genetic Variation	[130]
CNOT9	OT1NIIQD	Strong	Genetic Variation	[14]
CRNKL1	OTWBQNGU	Strong	Genetic Variation	[14]
DERA	OT8SMO3N	Strong	Biomarker	[131]
ERCC4	OTFIOPG1	Strong	Genetic Variation	[132]
ERCC5	OTQAKFJM	Strong	Genetic Variation	[133]
FARP1	OTL1EBTM	Strong	Altered Expression	[134]
GNAS	OTMH8BKJ	Strong	Genetic Variation	[14]
GOLGA4	OTCMEHNJ	Strong	Genetic Variation	[135]
HCP5	OTV0YRI8	Strong	Altered Expression	[136]
HOXC11	OT8NMHM6	Strong	Altered Expression	[137]
KIF18B	OTOBUDOE	Strong	Biomarker	[138]
KNSTRN	OTYA7UXS	Strong	Genetic Variation	[14]
LRAT	OTB7CJKY	Strong	Genetic Variation	[139]
MITF	OT6XJCZH	Strong	Biomarker	[140]
NCOA1	OTLIUJQD	Strong	Biomarker	[137]
NF1	OTC29NHH	Strong	Biomarker	[141]
OCA2	OTDWIGBF	Strong	Genetic Variation	[30]
PIK3R1	OT5BZ1J9	Strong	Genetic Variation	[14]
PLA2G6	OT5FL0WU	Strong	Genetic Variation	[48]
PPP6C	OTR1STMJ	Strong	Genetic Variation	[14]
SF3B2	OTNW2U4Y	Strong	Genetic Variation	[14]
SPINT1	OT1CLR5L	Strong	Genetic Variation	[142]
SPP2	OTX254AR	Strong	Genetic Variation	[143]
STIP1	OT7TXLOX	Strong	Altered Expression	[144]
STK11	OT1YZSP3	Strong	Posttranslational Modification	[145]
STK19	OTYM6437	Strong	Genetic Variation	[14]
TMSB10	OTLVZ13T	Strong	Biomarker	[146]
C11orf65	OTKOIR0G	Definitive	Genetic Variation	[48]
CD68	OTOYEY3J	Definitive	Biomarker	[11]
CLPTM1L	OTDJWQXI	Definitive	Genetic Variation	[48]
DOCK8	OTNQLL21	Definitive	Genetic Variation	[48]
FMN1	OT9CID5R	Definitive	Genetic Variation	[48]
GLT8D1	OTG14TPO	Definitive	Biomarker	[147]
GNA12	OT3IRZH3	Definitive	Biomarker	[148]
GPRC5A	OTPOCWR7	Definitive	Genetic Variation	[48]
MX2	OT05NF37	Definitive	Genetic Variation	[48]
NFIC	OTLMCUIB	Definitive	Genetic Variation	[48]
PELI1	OTMLBCLC	Definitive	Altered Expression	[149]
SYNE2	OTBUXGQ0	Definitive	Genetic Variation	[48]
TASOR2	OTN4VE8H	Definitive	Genetic Variation	[48]
TP53AIP1	OT1XVNDP	Definitive	Genetic Variation	[150]
TTC7B	OTUE51B3	Definitive	Genetic Variation	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 129 DOT(s)

References

1	Aldesleukin. 2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
2	Carboplatin FDA Label
3	Fludarabine FDA Label
4	Paclitaxel FDA Label
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Temozolomide FDA Label
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	ClinicalTrials.gov (NCT04830124) A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6. U.S.National Institutes of Health.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16(3):296-309.
11	The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.Melanoma Res. 2019 Jun;29(3):237-247. doi: 10.1097/CMR.0000000000000522.
12	Immunohistochemical profiling including beta-catenin in conjunctival melanocytic lesions.Exp Mol Pathol. 2017 Apr;102(2):198-202. doi: 10.1016/j.yexmp.2017.01.016. Epub 2017 Feb 1.
13	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.
14	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
15	Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.Fam Cancer. 2010 Dec;9(4):625-33. doi: 10.1007/s10689-010-9356-3.
16	Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer.Lab Invest. 1999 Dec;79(12):1615-27.
17	Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.Sci Rep. 2019 Aug 21;9(1):12150. doi: 10.1038/s41598-019-48635-x.
18	Expression of minichromosome maintenance proteins in Merkel cell carcinoma.J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1184-8. doi: 10.1111/j.1468-3083.2009.03285.x. Epub 2009 May 6.
19	MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway.J Cell Biochem. 2020 Feb;121(2):1283-1294. doi: 10.1002/jcb.29361. Epub 2019 Sep 18.
20	Aberrant NEK2 expression might be an independent predictor for poor recurrence-free survival and overall survival of skin cutaneous melanoma.Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3694-3702. doi: 10.26355/eurrev_201806_15248.
21	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy.Expert Opin Ther Targets. 2015 Jun;19(6):733-45. doi: 10.1517/14728222.2015.1045416.
22	Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2).Oncogene. 2010 May 27;29(21):3100-9. doi: 10.1038/onc.2010.63. Epub 2010 Mar 15.
23	RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.
24	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.
25	Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.Melanoma Res. 2017 Aug;27(4):309-314. doi: 10.1097/CMR.0000000000000360.
26	SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.PLoS One. 2017 Jun 29;12(6):e0180392. doi: 10.1371/journal.pone.0180392. eCollection 2017.
27	VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. doi: 10.1007/s00262-018-2169-1. Epub 2018 May 8.
28	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.Anticancer Res. 2018 Nov;38(11):6393-6397. doi: 10.21873/anticanres.12999.
29	Upregulation of LINC00963 facilitates melanoma progression through miR-608/NACC1 pathway and predicts poor prognosis.Biochem Biophys Res Commun. 2018 Sep 26;504(1):34-39. doi: 10.1016/j.bbrc.2018.08.115. Epub 2018 Sep 1.
30	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.Nat Genet. 2015 Sep;47(9):987-995. doi: 10.1038/ng.3373. Epub 2015 Aug 3.
31	HLA-DQB10303 and 0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population.Tissue Antigens. 1998 Jul;52(1):67-73. doi: 10.1111/j.1399-0039.1998.tb03025.x.
32	The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.Biomed Res Int. 2017;2017:5356737. doi: 10.1155/2017/5356737. Epub 2017 Nov 19.
33	Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.BMC Cancer. 2017 Dec 15;17(1):854. doi: 10.1186/s12885-017-3836-x.
34	Infrequent expression of the MAGE gene family in uveal melanomas.Int J Cancer. 1996 Jun 11;66(6):738-42. doi: 10.1002/(SICI)1097-0215(19960611)66:6<738::AID-IJC5>3.0.CO;2-0.
35	Regulation of melanotransferrin gene in melanoma cells. Analysis of the enhancer region.Biochim Biophys Acta. 1995 Feb 21;1260(3):301-7. doi: 10.1016/0167-4781(94)00208-k.
36	Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.Medicine (Baltimore). 2015 Aug;94(33):e1327. doi: 10.1097/MD.0000000000001327.
37	CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.PLoS One. 2010 Aug 27;5(8):e12452. doi: 10.1371/journal.pone.0012452.
38	Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.Hum Mutat. 2008 Dec;29(12):1443-51. doi: 10.1002/humu.20803.
39	The role of CCND1 alterations during the progression of cutaneous malignant melanoma.Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23.
40	Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.Int J Mol Med. 2019 Jan;43(1):404-412. doi: 10.3892/ijmm.2018.3985. Epub 2018 Nov 7.
41	Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells.Toxicol In Vitro. 2017 Apr;40:272-279. doi: 10.1016/j.tiv.2017.01.018. Epub 2017 Jan 26.
42	Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.Cancer Lett. 2018 Feb 1;414:268-277. doi: 10.1016/j.canlet.2017.11.027. Epub 2017 Nov 24.
43	CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.Int J Mol Sci. 2019 Jun 5;20(11):2764. doi: 10.3390/ijms20112764.
44	The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.Br J Dermatol. 2016 Dec;175(6):1210-1220. doi: 10.1111/bjd.14720. Epub 2016 Sep 13.
45	EGFL7 silencing inactivates the Notch signaling pathway; enhancing cell apoptosis and suppressing cell proliferation in human cutaneous melanoma.Neoplasma. 2019 Mar 5;66(2):187-196. doi: 10.4149/neo_2018_180310N167. Epub 2018 Sep 16.
46	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.Sci Immunol. 2019 Dec 13;4(42):eaax8189. doi: 10.1126/sciimmunol.aax8189.
47	The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.Cell Rep. 2017 Jul 25;20(4):854-867. doi: 10.1016/j.celrep.2017.07.007.
48	Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.Nat Commun. 2018 Nov 14;9(1):4774. doi: 10.1038/s41467-018-06649-5.
49	The mutational landscape of mucosal melanoma.Semin Cancer Biol. 2020 Apr;61:139-148. doi: 10.1016/j.semcancer.2019.09.013. Epub 2019 Oct 23.
50	Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.J Immunother. 2002 Jan-Feb;25(1):16-26. doi: 10.1097/00002371-200201000-00002.
51	Principles of Targeted Therapy for Melanoma.Surg Clin North Am. 2020 Feb;100(1):175-188. doi: 10.1016/j.suc.2019.09.013. Epub 2019 Nov 1.
52	Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12.
53	Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.Melanoma Res. 2019 Dec;29(6):590-595. doi: 10.1097/CMR.0000000000000578.
54	Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases.Int J Clin Oncol. 2010 Oct;15(5):453-6. doi: 10.1007/s10147-010-0087-0. Epub 2010 Apr 28.
55	Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.Endocr Pathol. 2014 Sep;25(3):324-31. doi: 10.1007/s12022-014-9303-1.
56	High SLC7A11 expression in normal skin of melanoma patients.Cancer Epidemiol. 2019 Oct;62:101582. doi: 10.1016/j.canep.2019.101582. Epub 2019 Aug 13.
57	Expression and functional role of CRIPTO-1 in cutaneous melanoma.Br J Cancer. 2011 Sep 27;105(7):1030-8. doi: 10.1038/bjc.2011.324. Epub 2011 Aug 23.
58	TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2330-2335. doi: 10.1167/iovs.19-26775.
59	Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.Mol Oncol. 2011 Apr;5(2):150-5. doi: 10.1016/j.molonc.2011.01.006. Epub 2011 Feb 3.
60	Lymphatic vessel density and VEGF-C expression as independent predictors ofmelanoma metastases.J Plast Reconstr Aesthet Surg. 2017 Nov;70(11):1653-1659. doi: 10.1016/j.bjps.2017.06.040. Epub 2017 Jul 8.
61	Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.Nat Genet. 2003 May;34(1):108-12. doi: 10.1038/ng1148.
62	Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.Br J Dermatol. 2016 Nov;175(5):1030-1037. doi: 10.1111/bjd.14897. Epub 2016 Aug 31.
63	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.Cancer Lett. 2019 Jun 28;452:178-190. doi: 10.1016/j.canlet.2019.03.023. Epub 2019 Mar 21.
64	Nestin expression in primary and metastatic uveal melanoma - possible biomarker for high-risk uveal melanoma.Acta Ophthalmol. 2018 Aug;96(5):503-509. doi: 10.1111/aos.13645. Epub 2018 Jan 16.
65	Novel Amide Derivatives as Potent Tyrosinase Inhibitors; In-vitro, In-vivo Antimelanogenic Activity and Computational Studies.Med Chem. 2019;15(7):715-728. doi: 10.2174/1573406415666190319101329.
66	Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.BMC Cancer. 2018 Jun 22;18(1):675. doi: 10.1186/s12885-018-4583-3.
67	M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.Melanoma Res. 2017 Jun;27(3):200-210. doi: 10.1097/CMR.0000000000000352.
68	Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma.Pigment Cell Melanoma Res. 2019 Nov;32(6):854-863. doi: 10.1111/pcmr.12804. Epub 2019 Jul 6.
69	Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance.Melanoma Res. 2019 Apr;29(2):151-156. doi: 10.1097/CMR.0000000000000548.
70	Influence of functional variants Asp312Asn and Lys751Gln of Xeroderma Pigmentosum Group D (XPD) and Glutathione S-transferase Mu 1 (GSTM1) and Theta 1 (GSTT1) genes on cutaneous melanoma susceptibility and prognosis.Exp Dermatol. 2019 May;28(5):631-635. doi: 10.1111/exd.13914.
71	Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure.Nat Commun. 2018 May 8;9(1):1684. doi: 10.1038/s41467-018-04086-y.
72	PRAS40 promotes NF-B transcriptional activity through association with p65.Oncogenesis. 2017 Sep 25;6(9):e381. doi: 10.1038/oncsis.2017.80.
73	EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma.Hum Pathol. 2005 Jan;36(1):74-81. doi: 10.1016/j.humpath.2004.10.015.
74	The plasma membrane Ca(2+) pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.Int J Cancer. 2017 Jun 15;140(12):2758-2770. doi: 10.1002/ijc.30503. Epub 2016 Nov 17.
75	Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1.Exp Cell Res. 2002 Feb 15;273(2):229-39. doi: 10.1006/excr.2001.5452.
76	Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.J Invest Dermatol. 2017 Aug;137(8):1749-1756. doi: 10.1016/j.jid.2017.04.023. Epub 2017 May 10.
77	Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation.Oncol Rep. 2018 Jul;40(1):123-144. doi: 10.3892/or.2018.6435. Epub 2018 May 16.
78	CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma.Postepy Dermatol Alergol. 2017 Jun;34(3):233-239. doi: 10.5114/ada.2017.67845. Epub 2017 May 29.
79	Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker.Int J Mol Sci. 2012;13(9):11044-11062. doi: 10.3390/ijms130911044. Epub 2012 Sep 5.
80	Prognostic Value of Dynactin mRNA Expression in Cutaneous Melanoma.Med Sci Monit. 2018 Jun 4;24:3752-3763. doi: 10.12659/MSM.910566.
81	SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.Acta Neuropathol Commun. 2016 Jan 15;4:5. doi: 10.1186/s40478-016-0272-0.
82	Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.J Invest Dermatol. 2010 Jan;130(1):221-9. doi: 10.1038/jid.2009.195.
83	Elevated kindlin-2 promotes tumour progression and angiogenesis through the mTOR/VEGFA pathway in melanoma.Aging (Albany NY). 2019 Aug 19;11(16):6273-6285. doi: 10.18632/aging.102187. Epub 2019 Aug 19.
84	Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma.Oncol Lett. 2018 May;15(5):7914-7922. doi: 10.3892/ol.2018.8306. Epub 2018 Mar 20.
85	A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.J Natl Cancer Inst. 2018 Dec 1;110(12):1380-1385. doi: 10.1093/jnci/djy058.
86	GRWD1 directly interacts with p53 and negatively regulates p53 transcriptional activity.J Biochem. 2020 Jan 1;167(1):15-24. doi: 10.1093/jb/mvz075.
87	Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma.BMC Cancer. 2013 Apr 5;13:181. doi: 10.1186/1471-2407-13-181.
88	Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.Clin Cancer Res. 2007 Jul 15;13(14):4111-6. doi: 10.1158/1078-0432.CCR-07-0408.
89	Giant Pediatric Rhabdoid Meningioma Associated with a Germline BAP1 Pathogenic Variation: A Rare Clinical Case.World Neurosurg. 2018 Nov;119:402-415. doi: 10.1016/j.wneu.2018.06.227. Epub 2018 Jul 6.
90	Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?.Clin Exp Metastasis. 2010 Aug;27(6):371-87. doi: 10.1007/s10585-010-9307-2. Epub 2010 Feb 24.
91	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.Clin Chem Lab Med. 2018 Oct 25;56(11):1945-1953. doi: 10.1515/cclm-2018-0139.
92	Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma.J Natl Cancer Inst. 2011 Aug 17;103(16):1227-35. doi: 10.1093/jnci/djr219. Epub 2011 Jun 21.
93	NAV2 facilitates invasion of cutaneous melanoma cells by targeting SNAI2 through the GSK-3/-catenin pathway.Arch Dermatol Res. 2019 Jul;311(5):399-410. doi: 10.1007/s00403-019-01909-w. Epub 2019 Apr 17.
94	Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma?.Histol Histopathol. 2003 Apr;18(2):529-39. doi: 10.14670/HH-18.529.
95	Adipophilin expression in cutaneous malignant melanoma.J Cutan Pathol. 2017 Mar;44(3):228-236. doi: 10.1111/cup.12868. Epub 2016 Dec 22.
96	P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.Cancer Lett. 2017 Oct 28;407:66-75. doi: 10.1016/j.canlet.2017.08.001. Epub 2017 Aug 10.
97	The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.Oncogene. 2000 Mar 9;19(11):1419-27. doi: 10.1038/sj.onc.1203462.
98	New Triterpenoids from the Stems of Cornus walteri.Chem Pharm Bull (Tokyo). 2017;65(7):683-686. doi: 10.1248/cpb.c17-00272.
99	RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.J Invest Dermatol. 2012 Mar;132(3 Pt 1):687-94. doi: 10.1038/jid.2011.380. Epub 2011 Nov 24.
100	Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas.Pathol Res Pract. 2011 Mar 15;207(3):174-81. doi: 10.1016/j.prp.2011.01.001.
101	Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?.Oncotarget. 2018 Apr 3;9(25):17656-17663. doi: 10.18632/oncotarget.24825. eCollection 2018 Apr 3.
102	Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.EBioMedicine. 2018 Nov;37:47-55. doi: 10.1016/j.ebiom.2018.10.002. Epub 2018 Oct 6.
103	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma.Clin Cancer Res. 2019 Dec 15;25(24):7585-7593. doi: 10.1158/1078-0432.CCR-19-1194. Epub 2019 Sep 30.
104	Linc00961 inhibits the proliferation and invasion of skin melanoma by targeting the miR?67/PTEN axis.Int J Oncol. 2019 Sep;55(3):708-720. doi: 10.3892/ijo.2019.4848. Epub 2019 Jul 25.
105	Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.Int J Cancer. 2015 Aug 1;137(3):638-45. doi: 10.1002/ijc.29429. Epub 2015 Jan 28.
106	TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin.Oncogene. 2000 Nov 23;19(50):5817-20. doi: 10.1038/sj.onc.1203961.
107	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma.Sci Rep. 2018 Dec 21;8(1):18036. doi: 10.1038/s41598-018-36173-x.
108	Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival.Pigment Cell Melanoma Res. 2016 Mar;29(2):176-85. doi: 10.1111/pcmr.12437. Epub 2016 Jan 29.
109	Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.Cancer Res. 2004 Mar 15;64(6):2245-50. doi: 10.1158/0008-5472.can-03-2932.
110	TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.Melanoma Res. 2012 Dec;22(6):430-5. doi: 10.1097/CMR.0b013e328358d9a2.
111	Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.Int J Cancer. 1998 Sep 25;78(1):13-5. doi: 10.1002/(sici)1097-0215(19980925)78:1<13::aid-ijc3>3.0.co;2-#.
112	Transcriptional regulation of ASK/Dbf4 in cutaneous melanoma is dependent on E2F1.Exp Dermatol. 2008 Dec;17(12):986-91. doi: 10.1111/j.1600-0625.2008.00730.x. Epub 2008 May 21.
113	Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma.Tumour Biol. 2014 Jan;35(1):123-7. doi: 10.1007/s13277-013-1015-5. Epub 2013 Aug 2.
114	MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project.Int J Cancer. 2015 Feb 1;136(3):618-31. doi: 10.1002/ijc.29018. Epub 2014 Jun 18.
115	Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.Front Genet. 2018 Dec 18;9:675. doi: 10.3389/fgene.2018.00675. eCollection 2018.
116	Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma.Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1101-10. doi: 10.1158/1055-9965.EPI-14-1380-T. Epub 2015 May 7.
117	Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling.Nucleic Acids Res. 2006 Aug 11;34(13):3819-32. doi: 10.1093/nar/gkl476. Print 2006.
118	Skeletrophin, a novel RING molecule controlled by the chromatin remodeling complex, is downregulated in malignant melanoma.DNA Cell Biol. 2005 May;24(5):339-44. doi: 10.1089/dna.2005.24.339.
119	Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma.Pathol Oncol Res. 2020 Jan;26(1):405-410. doi: 10.1007/s12253-018-0513-6. Epub 2018 Oct 30.
120	Molecular genetic analysis of NBS1 in German melanoma patients.Melanoma Res. 2007 Apr;17(2):109-16. doi: 10.1097/CMR.0b013e3280dec638.
121	Pax3 transcripts in melanoblast development.Dev Growth Differ. 2005 Dec;47(9):627-35. doi: 10.1111/j.1440-169X.2005.00835.x.
122	Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma.Kaohsiung J Med Sci. 2016 Oct;32(10):494-500. doi: 10.1016/j.kjms.2016.08.001. Epub 2016 Aug 27.
123	Cloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region.Gene. 1999 Oct 18;239(1):155-61. doi: 10.1016/s0378-1119(99)00354-6.
124	MiR-186 inhibits cell proliferation and invasion in human cutaneous malignant melanoma.J Cancer Res Ther. 2018;14(Supplement):S60-S64. doi: 10.4103/0973-1482.157340.
125	RASSF8 regulates progression of cutaneous melanoma through nuclear factor-b.Oncotarget. 2015 Oct 6;6(30):30165-77. doi: 10.18632/oncotarget.5030.
126	Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.Br J Cancer. 2014 May 13;110(10):2489-95. doi: 10.1038/bjc.2014.169. Epub 2014 Apr 10.
127	Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.J Dermatol Sci. 2017 Mar;85(3):216-225. doi: 10.1016/j.jdermsci.2016.12.002. Epub 2016 Dec 5.
128	Hypoxic Gene Signature of Primary and Metastatic Melanoma Cell Lines: Focusing on HIF-1 and NDRG-1.Balkan Med J. 2019 Dec 20;37(1):15-23. doi: 10.4274/balkanmedj.galenos.2019.2019.3.145. Epub 2019 Oct 9.
129	Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.Clin Cancer Res. 2008 Feb 1;14(3):638-45. doi: 10.1158/1078-0432.CCR-07-2025.
130	Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma.Br J Dermatol. 2011 May;164(5):1010-6. doi: 10.1111/j.1365-2133.2011.10223.x.
131	Establishment and characterization of a cell line (DEOC-1) originating from a human malignant melanoma of the skin.Hum Cell. 2007 May;20(2):23-38. doi: 10.1111/j.1749-0774.2007.00028.x.
132	XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma.Tumour Biol. 2016 Mar;37(3):3163-71. doi: 10.1007/s13277-015-4123-6. Epub 2015 Oct 2.
133	ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.J Invest Dermatol. 2011 Jun;131(6):1280-90. doi: 10.1038/jid.2011.35. Epub 2011 Mar 10.
134	FARP1 Facilitates Cell Proliferation Through Modulating MAPK Signaling Pathway in Cutaneous Melanoma.Am J Dermatopathol. 2019 Dec;41(12):908-913. doi: 10.1097/DAD.0000000000001426.
135	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.J Clin Invest. 2019 May 1;129(5):1940-1945. doi: 10.1172/JCI123089. Epub 2019 Mar 5.
136	Long noncoding RNA HCP5 suppresses skin cutaneous melanoma development by regulating RARRES3 gene expression via sponging miR-12.Onco Targets Ther. 2019 Aug 12;12:6323-6335. doi: 10.2147/OTT.S195796. eCollection 2019.
137	HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.Br J Cancer. 2011 Jun 28;105(1):118-23. doi: 10.1038/bjc.2011.193. Epub 2011 Jun 7.
138	Kinesin family member 18B: A contributor and facilitator in the proliferation and metastasis of cutaneous melanoma.J Biochem Mol Toxicol. 2019 Dec;33(12):e22409. doi: 10.1002/jbt.22409. Epub 2019 Oct 16.
139	Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters.Carcinogenesis. 2002 Nov;23(11):1821-30. doi: 10.1093/carcin/23.11.1821.
140	PAX3d mRNA over 2.76 copies/L in the bloodstream predicts cutaneous malignant melanoma relapse.Oncotarget. 2017 Aug 11;8(49):85479-85491. doi: 10.18632/oncotarget.20177. eCollection 2017 Oct 17.
141	An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.Cancer Discov. 2013 Mar;3(3):260-3. doi: 10.1158/2159-8290.CD-13-0017.
142	Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.J Exp Clin Cancer Res. 2019 Sep 13;38(1):405. doi: 10.1186/s13046-019-1389-3.
143	Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer.BMC Cancer. 2019 Dec 18;19(1):1230. doi: 10.1186/s12885-019-6441-3.
144	RETRACTED: Stress induced phosphoprotein 1 promotes tumor growth and metastasis of melanoma via modulating JAK2/STAT3 pathway.Biomed Pharmacother. 2019 Aug;116:108962. doi: 10.1016/j.biopha.2019.108962. Epub 2019 May 16.
145	Prognostic significance of LKB1 promoter methylation in cutaneous malignant melanoma.Oncol Lett. 2017 Aug;14(2):2075-2080. doi: 10.3892/ol.2017.6431. Epub 2017 Jun 20.
146	Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma.Int J Cancer. 1993 Jan 21;53(2):278-84. doi: 10.1002/ijc.2910530218.
147	GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.Melanoma Res. 2019 Dec;29(6):612-620. doi: 10.1097/CMR.0000000000000631.
148	Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.J Am Acad Dermatol. 2019 Jan;80(1):149-157.e4. doi: 10.1016/j.jaad.2018.07.028. Epub 2018 Aug 4.
149	Peli1 Modulates the Subcellular Localization and Activity of Mdmx.Cancer Res. 2018 Jun 1;78(11):2897-2910. doi: 10.1158/0008-5472.CAN-17-3531. Epub 2018 Mar 9.
150	Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.